Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability
Comprehensive Psychiatry · 2024
DOI: 10.1016/j.comppsych.2024.152486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comprehensive Psychiatry, 2024. Verfasst von Daniel Minkin Levy und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Jerusalem Mental Health Center, Eitanim, Jerusalem, Israel. Hauptthemen laut MEDLINE: Obsessive-Compulsive Disorder, Selective Serotonin Reuptake Inhibitors, Off-Label Use, Fluvoxamine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: To examine the long-term safety and tolerability of off-label high-dose serotonin reuptake inhibitors (OLHD-SRIs) in the treatment of obsessive-compulsive disorder (OCD). METHODS: A retrospective longitudinal study was performed on 105 randomly selected outpatients diagnosed with OCD and were treated with OLHD-SRIs for at least 6 months. Patients received sertraline >200 mg/day, escitalopram >20 mg/day, fluvoxamine >300 mg/day, and fluoxetine >60 mg/day, combined with exposure and response prevention therapy. Patients were divided into three dosing groups: sertraline equivalent dose (SED) ≤ 200 mg/day (n = 26, 24.7%), 201-400 mg/day (n = 51, 48.5%) and 401-650 mg/day (n = 28, 26.6%). Safety and tolerability were assessed with an electrocardiogram, blood biochemistry, complete blood count, and side-effects monitoring. RESULTS: SED ranged from 100 to 650 mg/day and the mean duration of OLHD-SRI treatment was 20.8 months. The most common side-effects reported were sexual dysfunction (n = 36, 34%), weight gain (n = 28, 27%), sedation (n = 27, 26%), hyperhidrosis (n = 20, 19%), and tremor (n = 11, 10%). Abnormal ECG was documented in one patient, and another patient experienced a first-time seizure, whereas elevated liver enzymes were seen in 4.8% of the sample (n = 5). None of the patients had serotonin syndrome or drug-induced liver injury. Side-effects did not differ among the three dosing groups. CONCLUSION: OLHD-SRIs appear to be safe and well tolerated in OCD patients in SED ≤ 650 mg/day doses and the side-effects did not differ between the three dosing groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jerusalem Mental Health Center, Eitanim, Jerusalem, Israel.
- Israeli Center for the Treatment of Obsessive-Compulsive and Related Disorders, Modiin, Israel.
- Israeli Center for the Treatment of Obsessive-Compulsive and Related Disorders, Modiin, Israel; Chaim Sheba Medical Center, Post Trauma Center, Ramat-Gan, Israel.
- Israeli Center for the Treatment of Obsessive-Compulsive and Related Disorders, Modiin, Israel; Chaim Sheba Medical Center, Post Trauma Center, Ramat-Gan, Israel; Tel Aviv University, Tel Aviv, Israel. Electronic addres…
Zitieren
APA
Levy, D. M., Arush, O. B., Carmi, L., Wetzler, A. J., & Zohar, J. (2024). Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability. Comprehensive Psychiatry. https://doi.org/10.1016/j.comppsych.2024.152486
Vancouver
Levy DM, Arush OB, Carmi L, Wetzler AJ, Zohar J. Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability. Comprehensive Psychiatry. 2024. doi:10.1016/j.comppsych.2024.152486
BibTeX
@article{Levy2024,
author = {Levy, Daniel Minkin and Arush, Oded Ben and Carmi, Lior and Wetzler, Alzbeta Juven and Zohar, Joseph},
title = {Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability},
journal = {Comprehensive Psychiatry},
year = {2024},
doi = {10.1016/j.comppsych.2024.152486}
}
EUVIMED